There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), Revance Therapeutics (RVNC – Research Report) and Abbott Labs (ABT – Research Report) with bullish sentiments. Mersana Therapeutics (MRSN) BTIG analyst Thomas Shrader maintained a Buy rating on Mersana Therapeutics on October 10 and set a price target of $32.00. The company's shares closed last Monday at $8.92, close to its 52-week low of $8.46. According to TipRanks.com, Shrader is a 4-star analyst with an average return of 8.8% and a 35.5% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Checkmate Pharmaceuticals, Minerva Neurosciences, and Precision BioSciences. Mersana Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.00, implying a 238.2% upside from current levels. In a report issued on October 8, H.C. Wainwright also maintained a Buy rating on the stock with a $28.00 price target. See today’s analyst top recommended stocks >> Revance Therapeutics (RVNC) Wells Fargo analyst Jacob Hughes reiterated a Buy rating on Revance Therapeutics yesterday. The company's shares closed last Monday at $27.30. According to TipRanks.com, Hughes is a 3-star analyst with an average return of 9.5% and a 71.4% success rate. Hughes covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Teva Pharmaceutical, and Mediwound. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $37.20 average price target. Abbott Labs (ABT) In a report issued on October 10, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Labs, with a price target of $135.00. The company's shares closed last Monday at $116.88. According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 18.1% and a 64.1% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Merit Medical Systems. Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $133.73, representing a 13.2% upside. In a report issued on October 1, Citigroup also maintained a Buy rating on the stock with a $140.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on MRSN: Analysts Offer Insights on Financial Companies: Healthequity (HQY), Blackstone Group (BX) and American Campus (ACC) INDUS Realty Trust (INDT) Receives a Buy from Robert W. Baird Adverum Biotechnologies (ADVM) Receives a Hold from Leerink Partners RegenXBio (RGNX) Receives a Hold from Leerink Partners Fundamental Research Maintains a Buy Rating on Quaterra Resources (QTRRF)